Download Citation
Article Source:
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
Wang Z,
Deng T,
Long X,
Lin X,
Wu S,
et al.
(2020)
Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
PLOS ONE 15(3): e0229754.
https://doi.org/10.1371/journal.pone.0229754